Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept SAN DIEGO and...
Thomas Heineman Timothy Mccarthy Jon Patton Matt Coffey Company Contact European Society For Medical Oncology
Source: marketscreener.com